Royal Marsden Shares Success Using Treatment Planning System for Radiotherapy Patients

Why It Matters

Deploying oART on standard linacs expands access to personalized radiotherapy, accelerating the NHS’s digital transformation and potentially lowering treatment costs while improving outcomes.

Key Takeaways

• Royal Marsden delivered oART on standard Elekta linac
• Adaptive planning occurs during each treatment session
• Reduces margins, side effects, and repeat scans
• Enables broader NHS rollout without new equipment
• Supports UK’s National Cancer Plan digital transformation goals

Pulse Analysis

Online adaptive radiotherapy represents a paradigm shift in oncologic care, moving from static treatment plans to daily, patient‑specific adjustments. By leveraging the Elekta linear accelerator’s imaging and delivery capabilities, clinicians can re‑optimize dose distributions on the fly, accounting for anatomical changes such as tumor shrinkage or organ motion. This real‑time adaptation not only sharpens tumor targeting but also trims the safety margins that traditionally protect surrounding healthy tissue, thereby reducing acute toxicity and long‑term side effects.

From an operational perspective, the Royal Marsden’s approach demonstrates that oART can be embedded within existing radiotherapy workflows without the capital outlay of dedicated adaptive machines. Hospitals can repurpose current linacs, preserving budgetary resources while expanding service capacity. The reduction in repeat imaging and fewer patient visits translates into lower ancillary costs and frees up appointment slots for other cases. Moreover, the streamlined process eases staffing pressures, as clinicians can adjust plans during the treatment session rather than scheduling separate planning sessions.

The initiative dovetails with the UK’s National Cancer Plan, which prioritises digital innovation, data integration, and patient‑centred pathways. Coupled with tools like the Cancer 360 dashboard, adaptive radiotherapy feeds richer clinical data into federated platforms, enhancing predictive analytics and supporting personalized treatment algorithms. As more trusts adopt oART, the NHS can accelerate its shift toward precision oncology, delivering higher‑quality care at scale while meeting policy goals for technology‑driven health transformation.